Abstract
Huntington’s disease is a devastating and complex disease that deeply impacts patients and their families. Changes in basic health, cognition, and personality tax patients, families, and caregivers. A collaborative team approach involving neuropsychologists and medical providers offering comprehensive evaluation and treatment in collaboration with patients and families enhances care of those with Huntington’s disease (HD).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Braun M, Tupper D, Kaufman P, et al. Neuropsychological assessment: a valuable tool in the diagnosis and management of neurological, neurodevelopmental, medical, and psychiatric disorders. Cogn Behav Neurol. 2011;24(3):107.
Troster A, editor. Clinical neuropsychology and cognitive neurology of Parkinson’s disease and other movement disorders. New York, NY: Oxford University Press; 2015.
Paulsen JS, Langbehn DR, Stout JC, et al PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Detection of Huntington’s disease decades before diagnosis: the PREDICT-HD study. J Neurol Neurosurg Pyschiatry 2008;79:874-880.
Pringsheim T, Wiltshire K, Day L, et al. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012;27(9):1083–91.
Harper PS. The epidemiology of Huntington’s disease. Hum Genet. 1992;89:365–76.
Vaccarino AL, Sills T, Anderson K, et al. Assessment of cognitive symptoms in prodromal and Huntington disease. PLoS Curr. 2011;25(3):RRN 1250.
Stout JC. (2011). Neurocognitive signs in prodromal Huntington disease. Neuropsychology. 2011;25(1):1–14.
MacLeod R, Tibben A, Frontali M, et al. Recommendations for the predictive genetic test in Huntington’s disease. Clin Genet. 2013;83:221–31.
Bates GP, MacDonald ME, Baxendale S, et al. Defined physical limits of the Huntington disease gene candidate region. Am J Hum Genet. 1991;49:7–16.
Wexler NS, Rose EA, Housman DE. Molecular approaches to hereditary diseases of the nervous system. Annu Rev Neurosci. 1991;14:503–29.
The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–83.
Kremer B, Goldberg P, Andrew SE, et al. A worldwide study of the Huntington’s disease mutation: the sensitivity and specificity of measuring CAG repeats. N Engl J Med. 1994;330:1401–6.
Rubinsztein DC, Leggo J, Coles R, et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet. 1996;59:16–22.
Killoran A, Biglan KM, Jankovic J, et al. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology. 2013;80:2022–7.
Maat-Kievet A, Losekoot M, Van den Boer-Van den Berg H, et al. New problems in testing for Huntington’s disease: the issue of intermediate and reduced penetrance alleles. J Med Genet. 2001;38:E12.
Potter NT, Spector EB, Prior TW. Technical standards and guidelines for Huntington disease testing. Genet Med. 2004;6:61–5.
Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nat Genet. 1993;4:387–92.
Brinkman RR, Mezei MM, Theilman J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet. 1997;60:1202–10.
Langbehn DR, Brinkman RR, Falush D, et al. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet. 2004 Apr;65(4):267–77.
Rosenblatt A, Kumar BV, Mo A, et al. Age, CAG repeat length, and clinical progression in Huntington’s disease. Mov Disord. 2012;27(2):272–6.
Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2011;82:405–10.
Dominguez DJF, Egan GF, Gray MA, et al. Multi-modal neuroimaging in premanifest and early Huntington’s disease: 18-month longitudinal data from the IMAGE-HD study. PLoS One. 2013;8(9):e74131.
Aylward EH, Rosenblatt A, Field K, et al. Caudate volume as an outcome measure in clinical trials for Huntington’s disease: a pilot study. Brain Res Bull. 2003;62:137–41.
Paulsen JS, Smith MM, Long JD. Cognitive decline in prodromal Huntington disease: implications for clinical trials. J Neurol Neurosurg Psychiatry. 2013;84(11):1233–9.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a Brief Screening Tool for Mild Cognitive Impairment. J Am Geriatr Soc. 2005;53(4):695–9.
Haaland KY, Dum RP, Mutha PK, Strick PL, Troster AI. The neuropsychology of movement and movement disorders: neuroanatomical and cognitive considerations. J Int Neuropsychol Soc. 2017;23:768–77.
Duff K, Paulsen JS, Mills J, et al; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Mild cognitive impairment in prediagnosed Huntington disease. Neurology. 2010;75(6):500-507.
Montoya A, Price BH, Menear M, Lepage M. Brain imaging and cognitive dysfunctions in Huntington’s disease. J Psychiatry Neurosci. 2006;31(1):21–9.
Chen JJ, Salat DH, Rosas HD. Complex relationships between cerebral blood flow and brain atrophy in early Huntington’s disease. Neuroimage. Jan 2018;59(2):1043–51.
Paradiso S, Turner BM, Paulsen JS, Jorge R, Ponto LL, Robinson RG. Neural bases of dysphoria in early Huntington’s disease. Psychiatry Res. 2008;162(1):73–87.
Alosco ML, Gunstad J, Jerskey BA, et al. The adverse effects of reduced cerebral perfusion on cognition and brain structure in older adults with cardiovascular disease. Brain Behav. 2013;3(6):626–36.
Beglinger LJ, Nopoulos PC, Jorge RE, et al. White matter volume and cognitive dysfunction in early Huntington’s disease. Cogn Behav Neurol. 2005;18:102–7.
McColgan P, Seunarine KK, Gregory S, et al. Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington’s disease. JCI Insight. 2017;2(8):e92641.
Dominguez JF, Poudel G, Stout J, et al. Longitudinal changes in the fronto-striatal network are associated with executive dysfunction and behavioral dysregulation in Huntington’s disease: 30 months IMAGE-HD data. Cortex. 2017;92:139–49.
Bonner-Jackson A, Long JD, Westerveld H, et al. Cognitive reserve and brain reserve in prodromal Huntington’s disease. J Int Neuropsychol Soc. 2013;19:739–50.
Zhang Y, Long JD, Mills JA, Warner JH, Lu W, Paulsen; and PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Indexing disease progression at study entry with individuals at risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet. 2011;156(7):751-763.
Harrington DL, Smith MM, Zhang Y, Carlozzi NE, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2012;83:612-619.
Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtis G. Wisconsin card sort test: manual, revised and expanded. Psychological Assessment Resources; 1993.
Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System (D-KEFS) Examiner’s Manual. San Antonio, TX: The Psychological Corporation; 2001.
Meyers JE, Meyers K. RCFT: Rey complex figure test and recognition trial, professional manual. Psychological Assessment Resources; 1995.
Koziol LF, Budding DE. Subcortical structures and cognition: implications for neuropsychological assessment. New York, NY: Springer; 2009.
Ho AK, Sahakian BJ, Brown RG, et al. Profile of cognitive progression in early Huntington’s disease. Neurology. 2003;61:1702–6.
Papp KV, Snyder PJ, Mills JA, et al. Measuring executive dysfunction longitudinally and in relation to genetic burden, brain volumetrics, and depression in prodromal Huntington disease. Arch Clin Neuropsychol. 2013;28:156–68.
Nicoll DR, Pirogovsky E, Woods SP, et al. "Forgetting to remember" in Huntington’s disease: a study of laboratory, semi-naturalistic, and self-perceptions of prospective memory. J Int Neuropsychol Soc. 2014;20:192–9.
Raskin S. Memory for Intentions Screening Test: psychometric properties and clinical evidence. Brain Impairment. 2009;10(1):23–33.
Strange PG. Brain biochemistry and brain disorders. Oxford: Oxford University Press; 1992.
Peavy GM, Jacobson MW, Goldstein JL, et al. Cognitive and functional decline in Huntington’s disease: dementia criteria revisited. Mov Disord. 2010;25(9):1163–9.
Smith A. Symbol digit modalities test manual. Western Psychological Services; 1982.
Paulsen JS, Butters N, Sadek JR, et al. Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology. 1995;45(5):951–6.
Ferm U, Sahlin A, Sundin L, Hartelius L. Using Talking Mats to support communication in personals with Huntington’s disease. Int J Lang Commun Disord. 2010;45(5):523–36.
Snowden JS, Craufurd D, Thompson J, Neary D. Psychomotor, executive, and memory function in preclinical Huntington’s disease. J Clin Exp Neuropsychol. 2002;24(2):133–45.
Snowden JS, Austin NA, Sembi S, Thompson JC, Craufurd D, Neary D. Emotion recognition in Huntington’s disease and frontotemporal dementia. Neuropsychologia. 2008;46(11):2638–49.
Grace J, Mallory P. FrSBe, Frontal Systems Behavior Scale: professional manual. Psychological Assessment Resources; 2001.
Lezak MD, Howieson DB, Bigler ED, Tranel D. Neuropsychological assessment: 5th edition. Oxford Press; 2012.
Stern Y. Cognitive reserve. Neuropsychologica. 2009;47(10):2015–28.
Koffler S, Morgan J, Baron IS, Greiffenstein MF. (eds) Neuropsychology: science and practice, I. Oxford Press; 2013.
Ionis Pharmaceuticals (2017). Dose-dependent reductions of mutant huntingtin protein observed; Ionis earns $45 million license fee. Press release of 11 December 2017. ir.ionispharma.com/news-releases. Accessed 25 Jan 2018.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this chapter
Cite this chapter
Sanders, K.M., Burdick, D.J. (2019). Huntington’s Disease Case Study. In: Sanders, K. (eds) Physician's Field Guide to Neuropsychology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-8722-1_19
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8722-1_19
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-8720-7
Online ISBN: 978-1-4939-8722-1
eBook Packages: MedicineMedicine (R0)